clinical trial · NCT03338816
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Acute Hepatic PorphyriaAcute Intermittent PorphyriaPorphyria, Acute IntermittentAcute PorphyriaHereditary Coproporphyria (HCP)Variegate Porphyria (VP)ALA Dehydratase Deficient Porphyria (ADP)GivosiranPlacebo
brief summary
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
started
Nov 16, 2017
primary completion
Jan 31, 2019
completion
May 31, 2021
last updated
Apr 22, 2024
official title
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol